ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 633

Missed Work Days in Systemic Lupus Erythematosus

Jie Xu1, Hong Fang2 and Michelle Petri2, 1Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Indirect costs are part of the medical and financial burden of SLE.  These costs are easy to undervalue because a significant portion of this economic loss results from lost productivity in the workforce (Clarke A, et al. Am J Manag Care, 2001; 7(16):S496-S501.).  This effect is magnified by the population typically affected by SLE, young women, who may suffer disabilities that affect the most productive years of life (Panopalis P, et al. Arthritis & Rheumatism, 2008; 59(12):1788-1795.).  We attempted to identify both demographic and disease variables that may serve as predictors of this loss in work-related activities.

Methods:  The medical resource use questionnaire was distributed to SLE patients in the Hopkins Lupus Cohort that covered the last 3 months before the baseline visit and then at the following two quarterly clinic visits. 199 SLE patients (89% female, 58% Caucasian, 31% African-American, 11% other ethnicities, mean age at baseline 44±11 years) were included in the analysis.  Exclusion criteria were diagnosis with lupus less than 6 months ago, age younger than 18 or older than 75, pregnant at baseline, and active HIV patients. Those who were unemployed were also excluded.

Results: The mean number of missed work days over 6 months was 2.6 days (range 0 to 39). Predictors of missed work days are shown in Table 1. The two significant predictors were low family income (p=0.019) and a history of missed work days in the 3 months before the study year (p<0.0001). A multivariate linear regression model for number of missed work days was then constructed (Table 2). In the multivariate model, disease activity (mean SLEDAI) was not associated with the number of missed work days. Renal activity (urine protein/cr ratio) had a borderline association. Family income was not predictive.

Table 1. Predictors of missed work days (any vs none) – univariate analysis.

 

 

Number (%) missed work days during followup

P-value

Age at baseline (years)

   ≤ 40 (n=86)

   > 40 (n=113)              

36 (41.9)

44 (38.9)

0.68

Gender

   Female (n=177)

   Male (n=22)

71 (40.1)

9 (40.9)

0.94

Ethnicity

 

   African-American (n=61)

   Caucasian (n=115)

29 (47.5)

42 (36.5)

0.16

Family income ($)

 

   ≤ 50K (n=75)

   > 50K (n=124)

38 (50.7)

42 (33.9)

0.019

Education (years)

 

   < 12 (n=7)

   ≥ 12 (n=192)

4 (57.1)

76 (39.6)

0.44

Use of prednisone at baseline

 

   No (n=126)

   Yes (n=73)

46 (36.5)

34 (46.6)

0.16

PGA1at baseline

 

   ≤1 (n=176)

   >1 (n=23)

67 (38.1)

13 (56.5)

0.090

Mean PGA over year

 

   ≤1 (n=170)

   >1 (n=29)

65 (38.2)

15 (51.7)

0.17

SLEDAI at baseline 

 

   ≤2  (n=154)

   >2 (n=45)

59 (38.3)

21 (46.7)

0.31

Mean SLEDAI over year 

 

   ≤2  (n=140)

   >2 (n=59)

54 (38.6)

26 (44.1)

0.47

Anti-dsDNA at baseline

 

   Negative (n=148)

   Positive (n=49)

58 (39.2)

21 (42.9)

0.65

C3 or C4 at baseline

 

   Low (n=40)

   Normal (n=156)

15 (37.5)

63 (40.4)

0.74

Increased ESR at baseline

 

   No (n=117)

   Yes (n=74)

46 (39.3)

31 (41.9)

0.72

Urine Pr:Cr ratio at baseline

   ≤0.5   (n=178)

   >0.5 (n=12)

70 (39.3)

7 (58.3)

0.23

Diabetes

 

   No (n=187)

   Yes (n=12)

72 (38.5)

8 (66.7)

0.070

BMI at baseline

 

   ≤30 (n=143)

   >30 (n=55)

52 (36.4)

27 (49.1)

0.10

Vitamin D

 

   <32 (n=57)

   ≥32 (n=137)

26 (45.6)

52 (38.0)

0.32

Baseline history of missed work days

   No (n=108)

   Yes (n=75)

22 (20.4)

52 (69.3)

<0.0001

 1PGA: Physician’s global assessment (0-3 scale)

Table 2. Multivariate Linear Regression Model

 

Effect on number of missed work days

P-value

Age at baseline (per 10 years)

0.03±0.04

0.39

Ethnicity (African-American)

0.19±0.91

0.83

Family income (>50K)

0.29±0.85

0.73

Mean SLEDAI (per unit)

0.05±0.20

0.79

Urine Pr:Cr ratio at baseline (per unit)

1.23±0.66

0.063

Diabetes

2.81±1.88

0.13

Vitamin D at baseline

-0.04±0.03

0.19

Number of missed work days at baseline

0.67±0.11

<0.0001

Conclusion: This study found that disease activity (either by physician’s global assessment or SLEDAI) is not predictive of missed work days. However, renal lupus had a borderline association. Demographic factors (sex, ethnicity, income) were not significant in the multivariate model. The most important factor remains a pattern of past history of missed work days.


Disclosure:

J. Xu,
None;

H. Fang,
None;

M. Petri,

HGS,

5,

GlaxoSmithKline,

5,

Medimmune,

5,

UCB,

5,

Anthera,

5,

Pfizer Inc,

5,

TEVA,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/missed-work-days-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology